重组人干扰素α1b不同给药途径在小儿手足口病治疗中的作用研究

Role research of different administration ways of recombinant human interferon α1b in treating pediatric hand foot mouth disease

目的探讨重组人干扰素α1b不同给药途径在小儿手足口病治疗中的作用,为重组人干扰素α1b在小儿手足口病治疗过程中提供临床循证参考。方法将2014年7月~2016年1月我科确诊为手足口病150例患儿按照入院治疗时间的先后顺序分为对照组30例,肌内注射组[1μg/（kg·次）和2μg/（kg·次）,均1次/d两个剂量亚组]各30例,雾化吸入组[2μg/（kg·次）和4μg/（kg·次）,均2次/d两个剂量亚组]各30例,疗程均为5 d。所有患儿都给予常规护理及退热等对症处理,伴细菌感染的给予抗生素治疗。比较各组患儿热退时间、皮疹消退时间、口腔疱疹消退时间、平均住院时间等临床疗效。结果重组人干扰素α1b 4个干预组与基础对照组临床表现及疗效组间比较,差异有统计学意义（P〈0.01）;重组人干扰素α1b小（大）剂量肌内注射组与小（大）剂量雾化吸入组临床表现及疗效组间比较,差异无统计学意义（P〉0.05）;重组人干扰素α1b肌内注射组及雾化吸入组临床表现及疗效各自组内比较,差异有统计学意义（P〈0.05）。结论重组人干扰素α1b治疗小儿手足口病可缩短病程,疗效确切;重组人干扰素α1b雾化吸入与肌内注射在小儿手足口病治疗中可取得相同疗效;重组人干扰素α1b相同给药途径下大剂量组较小剂量组效果更显著。

Objective To explore the role of different administration ways of recombinant human interferon α1b in treating pediatric hand foot mouth disease,and to provide clinical evidence-based reference for recombinant human interferon α1b in treating pediatric hand foot mouth disease.Methods According to the order of hospitalized time,150 children diagnosed hand foot mouth disease in our department from July 2014 to January 2016 were divided into control group（30 cases）,intramuscular injection group [n=30,1 μg/（kg·time） and 2 μg/（kg·time）,two dosage subgroups were for once a day],atomizing inhalation group [n=30,2 μg/（kg·time） and 4 μg/（kg·time）,two dosage subgroups were for twice a day）,and the course was 5 days.All of the patients were given symptomatic treatment liked routine nursing and pyretolysis,for patients with bacterial infection,antibiotic was used.Clinical effects of pyretolysis time,erythra regression time,Oral herpes regression time and average length of stay of children in each group were compared.Results The difference of clinical manifestation and effects of recombinant human interferon α1b among intervention groups and control group were statistical significance（P〈0.01）;The difference of clinical manifestation and effects between recombinant human interferon α1b small or large dosage intramuscular injection group and small or large dosage atomizing inhalation group had no statistical significance（P〉0.05）;The difference of clinical manifestation and effects of recombinant human interferonα1b intramuscular injection group and atomizing inhalation group within the group to compare were statistical significance（P〈0.05）.Conclusion Recombinant human interferon α1b in treating pediatric hand foot mouth disease can shorten the course of disease and with definite effects;Recombinant human interferon α1b atomizing inhalation in treating pediatric hand foot mouth disease can achieve the same effects with intramuscular injection;for same administration way,large dosage recombinant human interferon α1b has more obvious effects than small dosage.